Search Results for "covid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for covid. Results 71 to 80 of 93 total matches.
In Brief: Mifepristone by Mail for Pregnancy Termination
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
of the COVID-19
pandemic, will permanently allow mifepristone to
be dispensed by mail by certified ...
The FDA has removed the requirement that
mifepristone (Mifeprex, and generics), a progestin
receptor antagonist approved for use in a regimen with
the prostaglandin E1 analog misoprostol (Cytotec,
and generics) for medical termination of pregnancy,
must be dispensed in person to the patient.
Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines (online only) ...
View the Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines
Med Lett Drugs Ther. 2023 May 1;65(1675):e1 doi:10.58347/tml.2023.1675f | Show Introduction Hide Introduction
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
of anti-CD20 antibodies has
been associated with worse clinical outcomes in
patients with COVID-19.7,8 ...
The FDA has approved the recombinant chimeric
anti-CD20 antibody ublituximab-xiiy (Briumvi – TG Therapeutics) for IV treatment of adults with
relapsing forms of multiple sclerosis (MS), including
clinically isolated syndrome (initial neurological
episode), relapsing-remitting disease, and active
secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC
ofatumumab (Kesimpta), are also FDA-approved for
these indications.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):36-8 doi:10.58347/tml.2023.1671c | Show Introduction Hide Introduction
In Brief: Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
in the US and this increase has accelerated during
the COVID-19 pandemic.2 Studies of Emergency
Medical Services calls ...
The FDA has approved a higher-dose intranasal
naloxone formulation (Kloxxado – Hikma) for
emergency treatment of opioid overdose. A single
spray of the new formulation delivers 8 mg of
naloxone; a formulation that delivers 4 mg per spray
(Narcan) was approved in 2015.
Baricitinib (Olumiant) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
rheumatoid arthritis and treatment of COVID-19 in
certain hospitalized adults, has now been approved ...
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant – Lilly), which was previously approved by
the FDA for treatment of moderately to severely active
rheumatoid arthritis and treatment of COVID-19 in
certain hospitalized adults, has now been approved
for treatment of severe alopecia areata in adults.
Baricitinib is the first systemic treatment to be
approved in the US for this indication.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
antibiotic
treatment are at increased risk.1
INFLUENZA AND COVID-19 — Influenza and SARSCoV-
2 can also ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
are breastfeeding.
COVID-19 — COVID-19 has been associated with
inflammation and a prothrombotic state. In one ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Ofatumumab (Kesimpta) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
in patients with active HBV infection.
COVID-19 — Immunosuppressive therapy may
increase the risk ...
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has...
In Brief: Expanded Access to Mifepristone
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
misoprostol terminates early intrauterine
pregnancies in about 95% of women.
Before the COVID-19 pandemic ...
First approved in 2000 for termination of pregnancies
of ≤49 days' gestation, the indication for the oral
antiprogestin mifepristone (Mifeprex, and generics)
was expanded in 2016 to include pregnancies of
up to 10 weeks' gestation. A single 200-mg oral
dose of mifepristone followed 24-48 hours later by
a single 800-mcg buccal dose of the prostaglandin
analog misoprostol terminates early intrauterine
pregnancies in about 95% of women.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):31 doi:10.58347/tml.2023.1670c | Show Introduction Hide Introduction
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
with teriflunomide.
COVID-19 — Use of disease-modifying therapy
for treatment of MS has not been associated ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.